Moderna’s mRNA Tech Takes on Stomach Flu

The common stomach flu can end the misery. Pharmaceutical company Moderna has launched a large-scale Phase III trial that will test a vaccine against norovirus, a frequent and sometimes dangerous source of food poisoning.

of modern Nova 301 trial Following the first dose given to a volunteer last September, this year is set to kick into full gear. About 25,000 volunteers over the age of 18 are expected to enroll in the randomized, double-blinded and placebo-controlled trial, which will take two years to complete. People from all over the world will be able to participate in the study, including much of the United States

Norovirus is Major causes of foodborne illness In America, about 20 million cases occur each year. Most cases of norovirus are short-lived—if very uncomfortable—with diarrhea, vomiting, and flu-like illness lasting up to three days. For many, this is a sad but manageable ordeal. However, a significant number of people seek medical care, resulting in more than two million doctor visits and nearly half a million emergency room trips each year. In rare cases, the infection can become severe enough to result in hospitalization or even death. About 100,000 Americans are hospitalized by norovirus, while 900 die each year. It’s an even big problem In parts of the world with poor sanitation and health programs.

“Norovirus is a significant public health concern that affects millions of people worldwide each year, causing severe symptoms and, in some cases, hospitalization,” said Stephane Bansel, CEO of Moderna. statement Last fall “By advancing our investigational norovirus vaccine to a pivotal Phase 3 trial, we are one step closer to potentially providing a new tool to prevent infection from this highly contagious virus, which places a significant burden on health systems worldwide.”

Although norovirus has long been a thorn in humanity’s side, the urgency for a vaccine is surely greater now. After a brief lull throughout the early pandemic era, norovirus increased again in the United States in the latter half of 2024, with nearly 500 norovirus outbreaks reported, a substantial increase over the previous year. And this winter is norovirus season is on track Could be the worst experience in a decade.

Scientists have Struggled to develop A successful norovirus vaccine. Historically, we have not been able to grow the virus in the lab or in small animals, hampering our research. The virus is naturally tough on our defenses. Different types of disease-causing noroviruses circulate at any given time, and being recently infected with one strain does not necessarily protect you from others. Our natural immunity to a particular strain also wanes over time, presumably Lasts as little as a few months for some

But recently, scientists have been able to develop effective lab models for studying norovirus, and they have developed some promising techniques for vaccination. Moderna’s vaccine candidate, for example, tries to build immunity by training the body to target virus-like particles (VLPs) that closely resemble norovirus but lack the actual virus. Candidate uses the same basic mRNA technology applied to Moderna’s Covid-19 vaccines to accomplish this. mRNA vaccines induce cells in the body to produce a target protein that is then recognized by the immune system as a potential threat (in this case, norovirus VLPs).

The company’s candidate is code-named mRNA-1403, and it’s designed to induce immunity to at least three common types of norovirus, hopefully ensuring widespread protection. Although norovirus is a terrifying experience for everyone, it can cause serious illness in vulnerable populations such as those with weakened immune systems and the elderly. So most of the trial volunteers (20,000) will be over 60 years of age. Other companies are doing their own trials Norovirus vaccine for children Besides, anyway

There are more than 250 study sites for the NOVA 301 trial around the world, including more than 100 located in the United States alone. Participants had to be in generally good health (this could include well-controlled chronic health conditions), and no recent history of gastrointestinal illness, among other criteria. The main part of the trial is planned to run for two years, with completed results expected by May 2027. Those interested in potentially participating can take a survey created by Moderna here.